Pneuma Respiratory, Inc. Announces New Chairman of the Board

Food and Healthcare Press Releases Thursday August 22, 2019 12:39
BOONE, North Carolina--22 Aug--PRNewswire/InfoQuest
Pneuma Respiratory, Inc. announced that Board member Jay Morgan has assumed the position of Chairman of the Board. Pneuma's previous Chairman, Walt Robb, will remain a member of the Board of Directors.

Jay Morgan served as VP Global Innovation and Design for Bayer Consumer Care, VP Global Innovation for Merck Consumer Health and Chief Operating Officer - Research Operations for Merck Consumer Health globally. He is currently a founding partner of Pedal, a Knoxville based innovation agency that uses human-centered design to create new products, services and business models. Trained as a chemist at Ohio Northern University, his work lives at the intersection of human insight, technology and the requirements of business.

"We are honored to have Jay take on the responsibility of Chairman," stated Pneuma Chief Executive Officer and Co-founder Eric Hunter. "Jay's contributions as a member of our Board have been invaluable, and I look forward to working with him in his role as Chairman. I also want to thank Walt Robb for his advice and counsel as Chairman, as well as his ongoing commitment to Pneuma as a valued member of the Board."

At the time of his appointment as Chairman, Jay Morgan stated, "When I joined the Board of Pneuma Respiratory, I was impressed by the strength and depth of the organization and the unique capability of the technology. We will continue to build a world-class company delivering a broad range of drugs and formulations through the lungs. I look forward to working with Eric and the team as Chairman to achieve that goal."

"Having worked with Jay Morgan on the Board of Directors, I can unequivocally state he is an outstanding choice to provide leadership as the Chairman of Pneuma Respiratory," said Walt Robb. "I am excited about our future and welcome the opportunity to continue to serve as a member of the Board."

About Pneuma Respiratory

Launched in 2015, Pneuma Respiratory is a pharmaceutical company based in Boone, North Carolina. With a global team of researchers, physicians, designers and engineers, Pneuma has the first fully integrated digital breath activated inhaler. Using Pneuma's digital droplet ejector technology, Pneuma's device, although currently available for investigational purposes only, can deliver a spectrum of novel therapies, including biologics, to the lungs. For more information visit www.pneumarespiratory.com

Contact:
Christy Anglin
canglin@pneumarespiratory.com
Logo - https://mma.prnewswire.com/media/887236/Pneuma_Respiratory_Logo.jpg

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics